Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie R Earnshaw

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Clinical Therapeutics|June 15, 2012
Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United KingdomStephanie R Earnshaw, Cheryl McDade, Ann-Marie Chapman, et al.
Patient Preference and Adherence|March 9, 2012
Spillover adherence effects of fixed-dose combination HIV therapyTeresa L Kauf, Keith L Davis, Stephanie R Earnshaw, et al.
Managed Care Interface|November 4, 2005
A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumoniaStephanie R Earnshaw, Sean D Candrilli, Ancilla W Fernandes, et al.
BMC Infectious Diseases|April 26, 2012
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in CanadaStephanie R Earnshaw, Cheryl L McDade, Giovanni Zanotti, et al.
Applied Health Economics and Health Policy|September 8, 2009
Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosisStephanie R Earnshaw, Jonathan Graham, MerriKay Oleen-Burkey, et al.
Clinical Therapeutics|March 29, 2017
Cost-effectiveness of Maintaining Daily Intake of Oat β-Glucan for Coronary Heart Disease Primary PreventionStephanie R Earnshaw, Cheryl L McDade, YiFang Chu, et al.
Journal of the American Society of Nephrology : JASN|June 20, 2008
Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantationStephanie R Earnshaw, Christopher N Graham, William D Irish, et al.
Pharmacoeconomics|March 4, 2010
Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populationsStephanie R Earnshaw, Cheryl L McDade, Libby K Black, et al.
Applied Health Economics and Health Policy|August 31, 2011
Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trialMichael W Kattan, Stephanie R Earnshaw, Cheryl L McDade, et al.
Microbiology Spectrum|May 9, 2022
Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United KingdomStephanie R Earnshaw, Cheryl McDade, Andrew Bryan, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Clinical Therapeutics|June 15, 2012
Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United KingdomStephanie R Earnshaw, Cheryl McDade, Ann-Marie Chapman, et al.
Patient Preference and Adherence|March 9, 2012
Spillover adherence effects of fixed-dose combination HIV therapyTeresa L Kauf, Keith L Davis, Stephanie R Earnshaw, et al.
Managed Care Interface|November 4, 2005
A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumoniaStephanie R Earnshaw, Sean D Candrilli, Ancilla W Fernandes, et al.
BMC Infectious Diseases|April 26, 2012
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in CanadaStephanie R Earnshaw, Cheryl L McDade, Giovanni Zanotti, et al.
Applied Health Economics and Health Policy|September 8, 2009
Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosisStephanie R Earnshaw, Jonathan Graham, MerriKay Oleen-Burkey, et al.
Clinical Therapeutics|March 29, 2017
Cost-effectiveness of Maintaining Daily Intake of Oat β-Glucan for Coronary Heart Disease Primary PreventionStephanie R Earnshaw, Cheryl L McDade, YiFang Chu, et al.
Journal of the American Society of Nephrology : JASN|June 20, 2008
Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantationStephanie R Earnshaw, Christopher N Graham, William D Irish, et al.
Pharmacoeconomics|March 4, 2010
Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populationsStephanie R Earnshaw, Cheryl L McDade, Libby K Black, et al.
Applied Health Economics and Health Policy|August 31, 2011
Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trialMichael W Kattan, Stephanie R Earnshaw, Cheryl L McDade, et al.
Microbiology Spectrum|May 9, 2022
Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United KingdomStephanie R Earnshaw, Cheryl McDade, Andrew Bryan, et al.
Pageof 4